2-(4-oxazol-4-yl-phenoxy)-ethylamine | 416859-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-oxazol-4-yl-phenoxy)-ethylamine
• 英文别名: 2-[4-(1,3-oxazol-4-yl)phenoxy]ethanamine
• CAS: 416859-73-9
• 化学式: C₁₁H₁₂N₂O₂
• 分子量: 204.228
• InChiKey: YKKTVVVZWNXYGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  61.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-oxazol-4-yl-phenoxy)-ethylamine 、 2-chloro-5-[(2R)-2-oxiranyl]pyridine 在 TMS acetamide 作用下， 以 四氢呋喃 为溶剂， 以58%的产率得到(1R)-1-(6-chloropyridin-3-yl)-2-[2-[4-(1,3-oxazol-4-yl)phenoxy]ethylamino]ethanol
  参考文献：
  名称：

  Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity

  摘要：

  A novel series of heterocycle-based analogs were prepared and evaluated for their in vitro and in vivo biological activity as human beta(3)-adrenergic receptor (AR) agonists. Several analogs demonstrated potent agonist activity at the beta(3)-AR, functional selectivity against beta(1)- and beta(2)-ARs, and favorable pharmacokinetic profiles in vivo. Compound 17 increased oxygen consumption in rats, a measure of energy expenditure, with an EDO20% of 2 mg/kg. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.072
• 作为产物：
  描述：

  [2-(4-oxazol-4-yl-phenoxy)-ethyl]-carbamic acid benzyl ester 在 palladium 10% on activated carbon 1,4-环己二烯 作用下， 以 甲醇 为溶剂， 反应 22.0h， 以81.5%的产率得到2-(4-oxazol-4-yl-phenoxy)-ethylamine
  参考文献：
  名称：

  [EN] SALT OF A PYRIDYL ETHANOLAMINE DERIVATIVE AND ITS USE AS A BETA-3-ADRENERGIC RECEPTOR AGONIST
  [FR] SEL D'UN DERIVE DE PYRIDYLE ETHANOLAMINE ET SON UTILISATION EN TANT QU'AGONISTE DU RECEPTEUR BETA-ADRENERGIQUE

  摘要：

  本发明提供了(R)-2-(2-(4-噁唑-4-基-苯氧基)-乙基氨基)-1-吡啶-3-基-乙醇的对磺酸盐，该盐的单水合物，用于制备该盐和该单水合物的有用过程，包括该盐或该单水合物的药物组合物，使用该盐、该单水合物或该药物组合物在哺乳动物中治疗ß3-肾上腺素受体介导的疾病、症状和障碍的方法；以及使用该盐、该单水合物或该药物组合物增加食用动物中瘦肉含量的方法。

  公开号：

  WO2003072571A1

文献信息

• Bita3 adrenergic receptor agonists and uses thereof
  申请人：——

  公开号：US20020052392A1

  公开（公告）日：2002-05-02

  The instant invention provides &bgr; 3 adrenergic receptor agonists of structural Formula (I), 1 the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating &bgr; 3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.

  本发明提供了结构式（I）的β3肾上腺素受体激动剂，其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐，其中Ar、R、R1、R2、R3、R4、R5、R6、R7、R8、X和Y的定义如本文所述。本发明还提供了在制备结构式（I）化合物中有用的中间体，结构式（I）化合物的组合，其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐与抗肥胖药物的组合；包括结构式（I）化合物、其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐的药物组合；或包括结构式（I）化合物、其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐，以及抗肥胖药物的药物组合的药物组合；以及治疗β3肾上腺素受体介导的疾病、症状或障碍的方法，该方法包括向哺乳动物施用结构式（I）化合物、其立体异构体或前药的有效量，或其药物组合；或者结构式（I）化合物、其药用盐、立体异构体或前药，以及抗肥胖药物的组合，或其药物组合。
• Processes and intermediates useful in preparing beta3-adrenergic receptor agonists
  申请人：——

  公开号：US20030199046A1

  公开（公告）日：2003-10-23

  The present invention provides processes useful in the preparation of certain &bgr; 3 -adrenergic receptor agonists of the structural formula 1 the pharmaceutically acceptable salts thereof, and the hydrates of said pharmaceutically acceptable salts, wherein HET is as described herein. The invention further provides intermediates useful in the preparation of such agonists, and processes useful in the production of such intermediates.

  本发明提供了在制备特定的β3-肾上腺素受体激动剂的过程中有用的方法，其结构式如下：其中HET如本文所述。该发明还提供了在制备这类激动剂中有用的中间体，以及在生产这类中间体中有用的过程。
• [EN] SALT OF A PYRIDYL ETHANOLAMINE DERIVATIVE AND ITS USE AS A BETA-3-ADRENERGIC RECEPTOR AGONIST<br/>[FR] SEL D'UN DERIVE DE PYRIDYLE ETHANOLAMINE ET SON UTILISATION EN TANT QU'AGONISTE DU RECEPTEUR BETA-ADRENERGIQUE
  申请人：PFIZER PROD INC

  公开号：WO2003072571A1

  公开（公告）日：2003-09-04

  The present invention provides the tosylate salt of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol, the monohydrate of such salt, processes useful in the preparation of such salt and such monohydrate, pharmaceutical compositions comprising such salt, or such monohydrate, methods of treating ß3-adrenergic receptor-mediated diseases, conditions, and disorders in a mammal using such salt, such monohydrate, or such pharmaceutical compositions; and methods of increasing the content of lean meat in edible animals using such salt, such monohydrate, or such pharmaceutical compositions.

  本发明提供了(R)-2-(2-(4-噁唑-4-基-苯氧基)-乙基氨基)-1-吡啶-3-基-乙醇的对磺酸盐，该盐的单水合物，用于制备该盐和该单水合物的有用过程，包括该盐或该单水合物的药物组合物，使用该盐、该单水合物或该药物组合物在哺乳动物中治疗ß3-肾上腺素受体介导的疾病、症状和障碍的方法；以及使用该盐、该单水合物或该药物组合物增加食用动物中瘦肉含量的方法。
• Beta3 adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof
  申请人：Pfizer Inc.

  公开号：US20030166686A1

  公开（公告）日：2003-09-04

  The present invention provides the tosylate salt of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol, the monohydrate of such salt, processes useful in the preparation of such salt and such monohydrate, pharmaceutical compositions comprising such salt, or such monohydrate, methods of treating &bgr; 3 -adrenergic receptor-mediated diseases, conditions, and disorders in a mammal using such salt, such monohydrate, or such pharmaceutical compositions; and methods of increasing the content of lean meat in edible animals using such salt, such monohydrate, or such pharmaceutical compositions.

  本发明提供了(R)-2-(2-(4-噁唑-4-基-phenoxy)-乙基氨基)-1-吡啶-3-基-乙醇的对磺酸盐，该盐的单水合物，用于制备该盐和该单水合物的有用工艺，包括该盐或该单水合物的药物组合物，使用该盐、该单水合物或该药物组合物治疗β3-肾上腺素受体介导的疾病、症状和障碍的方法，以及使用该盐、该单水合物或该药物组合物增加食用动物中瘦肉含量的方法。
• Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists
  申请人：Pfizer Inc

  公开号：US20040077871A1

  公开（公告）日：2004-04-22

  The present invention provides processes useful in the preparation of certain &bgr; 3 -adrenergic receptor agonists of the structural formula 1 the pharmaceutically acceptable salts thereof, and the hydrates of said pharmaceutically acceptable salts, wherein HET is as described herein. The invention further provides intermediates useful in the preparation of such agonists, and processes useful in the production of such intermediates.

  本发明提供了在制备某些结构式1的β3-肾上腺素受体激动剂中有用的过程，其药物可接受的盐以及所述药物可接受的盐的水合物，其中HET如本文所述。本发明还提供了在制备这种激动剂中有用的中间体，以及在生产这种中间体中有用的过程。